Deucrictibant

N/A

Report date: 2026/05/15 20:01:45
NME

Base Information

Drug NameDeucrictibant
Drug Alias NamePHA-121PHA-022121PHVS-416PHVS 719PHVS416 - soft capsule formulation +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBradykinin B2 receptor antagonists
TargetsBradykinin B2 receptor
Therapy Area/IndicationsHereditary Angioedema Types I and IIHereditary Angioedema Type IIIAngioedemas, Hereditary +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBulgariaCanada +[35] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesPharvaris Netherlands BV
China Registration ClassN/A

Develop Information

Active CompaniesInstitute for Asthma and AllergyPharvaris Netherlands BVRoyalty Pharma +[5] 
Inactive CompaniesN/A
Active IndicationsHereditary Angioedema Types I and IIHereditary Angioedema Type IIIAngioedemas, Hereditary +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A